Skip to content
TheChatArchiveThe Chat Archive
gpt-3.5-turbo-0125· OpenAIAi2 WildChat-4.8M (AI2)

summarize this: 1E Therapeutics announced $120 million seed funding, a remarkable feat…

  1. User

    summarize this: 1E Therapeutics announced 120millionseedfunding,aremarkablefeatforanearly−stagebiotechcompany.ThefundingisthelargestofitskindforanIsraelibiotechcompany.Today,1ETherapeuticsannounceditraised120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company. Today, 1E Therapeutics announced it raised 120 million for its seed funding round. The funding is believed to be the largest of its kind for an Israeli biotech company.

    A relatively new player founded five months ago, 1E is taking key steps to launch a first-in-class RNA-targeting therapeutics based on a proprietary drug design platform.

    Details about the company are limited, but according to reports from employees, the 1E offices and laboratories in the Rehovot Science Park, in Israel are comparable to those of big established companies. One employee was quoted saying, “I have never seen such a collection of advanced equipment in one lab, not in the industry or in the academy. I estimate that the cost of the equipment alone came to tens of millions of dollars.” The company has dozens of researchers and is expanding its team.

    No details about the company’s activity in the building are available now, but its one-page website offers more information about the drug company, stating, “1E’s groundbreaking process has proven uniquely able to develop innovative drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.”

    Dr. Ido Bachelet, a Ph.D. in medical sciences from Hebrew University who completed his postdoctoral training at MIT and Harvard at the George Church laboratory, is 1E’s lead scientist. Dr. Bachelet is a recognized innovator in therapeutic DNA origami, synthetic biology, biomimetics, and several companies’ founder.

    Serial entrepreneur Marius Nacht, one of the co-founders of Check Point and currently considered the most prominent Israeli investor active in the biotech and medtech industries, is one of the top financiers in the company. Nacht’s investment portfolio includes companies in life sciences, healthcare, software, AI, mobility, cyber security, sustainability, energy, and semiconductors.

    It is not the first time Bachelet and Nacht have collaborated in business. They have worked together several times in the past, including in Wild Biotech company, a preclinical stage drug discovery and development company developing an AI-powered drug-discovery platform that can jumpstart the creation of new medicines for treating the incurable.

  2. Assistant

    1E Therapeutics has secured $120 million in seed funding, which is the largest of its kind for an Israeli biotech company. Founded five months ago, the company is focused on developing RNA-targeting therapeutics and has a state-of-the-art facility in the Rehovot Science Park. The company's website states that they are working on drugs for a variety of indications, including oncology, age-related diseases, and viral infections. Lead scientist Dr. Ido Bachelet, who has a background in medical sciences and has worked at MIT and Harvard, is leading the research efforts. The company is backed by serial entrepreneur Marius Nacht, a co-founder of Check Point and a prominent Israeli investor in the biotech and medtech industries. Bachelet and Nacht have previously collaborated in business ventures, including in a preclinical stage drug discovery company.

  3. User

    summarize more

  4. Assistant

    1E Therapeutics, an early-stage biotech company founded five months ago, has raised a record-breaking $120 million in seed funding, the largest ever for an Israeli biotech company. The company, focused on developing RNA-targeting therapeutics, boasts a cutting-edge facility in Israel's Rehovot Science Park. Lead scientist Dr. Ido Bachelet, with a background in medical sciences and experience at MIT and Harvard, is spearheading the research efforts. Backed by serial entrepreneur Marius Nacht, a prominent Israeli investor, 1E Therapeutics is working on innovative drugs for a range of indications, including oncology and viral infections. Bachelet and Nacht have a history of successful collaboration in the business sector, including in a preclinical stage drug discovery company.

  5. User

    briefer

  6. Assistant

    1E Therapeutics, a new Israeli biotech company, has raised a record $120 million in seed funding. The company is focused on developing RNA-targeting therapeutics and boasts a state-of-the-art facility in the Rehovot Science Park. Lead scientist Dr. Ido Bachelet, with experience at MIT and Harvard, is heading the research efforts, backed by prominent investor Marius Nacht. The company is working on innovative drugs for various indications, including oncology and viral infections. Bachelet and Nacht have a successful history of collaboration in the business sector.

  7. User

    summarize this: In the past few years, a few Israeli entrepreneurs have pushed new applications, however, most have faced market barriers. To address those barriers, the IIA, together with other Israeli stakeholders from the government, industry, VCs, and academia, began planning how to close those gaps. One option was using a unique local infrastructure facility, which will serve as an enabler for the translation of ideas to the marketplace. The IIA had announced a call for proposals for a new company that would serve as the first Israeli Bio‐Foundry. The IIA offered 55% of 40M NIS for any group that can develop a professional service vision with internal financial capabilities in a short time frame of two to 3 years. The winning team was a unique combination of a classical biotech service company, Hylabs Ltd., Reichman University, and VC investors led by Michael Eisenberg. The new company, Alagene, started officially in March 2022 and is already operational, serving its first customers. This facility is only one example out of many initiatives of the Israeli government to push the local ecosystem forward. Alagene's vision is to become a SynBio powerhouse and to nourish the international SynBio ecosystem by providing cutting‐edge SynBio R&D services; alleviating technological, operational, and knowhow‐related barriers; making frontline practices associated with computational design and engineering of genes and organisms; and making high‐throughput constructing and screening, analytics, precision fermentation, and prototyping accessible for all across the academy and industry (See Figure 2). The allocated budget also enabled the company to bring back SynBio experts from the USA and to hire brilliant local leaders. Alagene Ltd. is composed of a seasoned and highly skilled scientific team, equipped with state‐of‐the‐art instrumentation, to bring to fulfilment ambitious SynBio development processes such as optimization of catalysts, heterologous production of biomolecules, design of novel genetic programs and reporter systems, and many more applications. Alagene offers an inclusive development pipeline that follows the Design‐Build‐Test‐Learn paradigm and is divided into four operation modules. The Computational Design module (module 1 in Figure 2. B) employs data science, structural biology, and bioinformatics to generate data and AI‐ driven predictions aiming to direct the biological system towards its applicative designation. The Construct and Host Engineering module (module 2) utilises genetic engineering procedures and automation to streamline the construction of genetic libraries, composed of variants generated by rational‐ design or randomisation approaches. The Optimization by Automation and Analytics module (module 3) makes use of automation to screen numerous variants in a high throughput manner in a fast, accurate, and cost‐efficient manner. Sophisticated analytic methods determine analyte structure and quantity. The Precision Fermentation, Pre‐Production and proof of concept (POC) module (module 4) is taking the genetic optimization effort the extra mile towards commercialisation by complementing the superior genetics with process development, for optimising its performance in applications such as bioproduction or implementation of the engineered system in a given use case. This development process ultimately supports SynBio product development from the very early ideation phase up to the completion of a POC. Alagene collaborates with academic groups, industrial ventures, and national institutes in various projects, associated with multiple industries, including pharma, cosmetics, ag‐tech, cleantech, food‐tech, materials, energy, and defence. One example can be found in Figure 2c. Engineering life for the benefit of humanity, Alagene is quickly becoming a leader in the global market, side by side with other bio‐foundries, some of which are mentioned in Figure 3. Alagene is a home for innovation and R&D in SynBio, serving as a one‐stop—shop for knowledge, methods, and instrumentation to enable customers in Israel and worldwide to get to their POC.

  8. Assistant

    The Israeli government, in collaboration with various stakeholders, established Alagene as the first Israeli Bio-Foundry to overcome market barriers in the biotech industry. Alagene aims to become a global leader in synthetic biology research by providing cutting-edge services, such as computational design, gene engineering, optimization, and fermentation. The company offers a comprehensive development pipeline and collaborates with academic and industrial partners in various sectors. Alagene is positioned to drive innovation in synthetic biology, offering expertise and resources to customers globally.

  9. User

    more comprehensive

  10. Assistant

    Several Israeli entrepreneurs have recently faced challenges in bringing new applications to the market due to various barriers. In response, the Israel Innovation Authority (IIA) collaborated with government entities, industry players, venture capitalists, and academia to address these obstacles. One strategy involved establishing a local infrastructure facility to facilitate the translation of innovative ideas into market-ready products. The IIA issued a call for proposals to create the first Bio-Foundry in Israel, offering funding incentives for the development of this initiative.

    Alagene emerged as the winning team, comprising the biotech service company Hylabs Ltd., Reichman University, and investment partners led by Michael Eisenberg. Officially starting operations in March 2022, Alagene seeks to become a powerhouse in synthetic biology (SynBio) by offering advanced research and development services to a global clientele. The company's vision includes overcoming technological and operational barriers, providing expertise in computational design and genetic engineering, and offering high-throughput construction and screening capabilities.

    With a significant budget allocation, Alagene has recruited top SynBio experts from the USA and locally to lead its scientific team and employ state-of-the-art technologies. The development process at Alagene follows a Design-Build-Test-Learn paradigm, divided into four operation modules: Computational Design, Construct and Host Engineering, Optimization by Automation and Analytics, and Precision Fermentation, Pre-Production, and Proof of Concept.

    Moreover, Alagene collaborates with academic institutions, industrial ventures, and national research institutes across various sectors, including pharmaceuticals, cosmetics, agri-tech, clean technology, food technology, materials, energy, and defense. By promoting innovation and research in SynBio, Alagene aims to become a global leader alongside other bio-foundries worldwide. The company provides a comprehensive range of services, from ideation to proof of concept, establishing itself as a key facilitator of synthetic biology advancements for customers both in Israel and internationally.

  11. User

    summarize this: The Israeli generic bio‐chip technology R&D consortium The Bio‐Chip consortium consists of 7 industrial companies (Tower SC, CEVA, PLSense QuLab medical, Cardiokol, SensoMedical, Israel Aerospace Industry) and 12 research groups from 4 different academic institutes (The Technion IIT, BIU, BGU and TAU). The main goal of the consortium is to develop and bring to market innovative‐generic Bio‐ chips technologies that will be available for the emerging Israeli Bio‐Medical sector and will bridge the currently existing gap in the industry. The consortium develops various biosensors and supportive technologies with an emphasis on innovative low‐power circuits, chip manufacturing technologies, microfluidics, optical applications, and AI capabilities needed for bio‐chip‐based systems. The technologies will be demonstrated in metabolic sensing, innovative heart‐ arrhythmia detection, analog biosensors, EEG, SynBio, and more.

  12. Assistant

    The Israeli Generic Bio-Chip Technology R&D Consortium comprises seven industrial companies and 12 research groups from four academic institutes. The primary objective of the consortium is to develop and commercialize innovative generic bio-chip technologies for the Israeli biomedical sector, addressing current industry gaps. The consortium focuses on developing biosensors and related technologies, emphasizing low-power circuits, chip manufacturing, microfluidics, optics, and AI capabilities essential for bio-chip systems. The technologies will be applied in various areas such as metabolic sensing, heart arrhythmia detection, analog biosensors, EEG, and synthetic biology.